Author

A. Virtanen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Assay:bulk RNA-seq· 4 Research Focus:drug response / drug discovery· 4 Research Focus:differential expression· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Research Focus:gene regulatory network inference· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

S. Hautaniemi· 5 shared E. P. Erkan· 4 shared J. Hynninen· 4 shared J. Oikkonen· 4 shared Y. Li· 4 shared K. Lavikka· 3 shared M. M. Falco· 3 shared A. Farkkila· 2 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

S. Hautaniemi

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Multi-Omics Analysis Reveals the Attenuation of the Interferon Pathway as a Driver of Chemo-Refractory Ovarian Cancer

D. Afenteva, R. Yu, A. Rajavuori, M. Salvadores, I.-M. Launonen, K. Lavikka, K. Zhang, G. Marchi, S. Jamalzadeh, V.-M. Isoviita, Y. Li, G. Micoli, E. P. Erkan, M. M. Falco, D. Ungureanu, , S. Hautaniemi

The paper identifies reduced IFN-I pathway activity as a driver of chemo-refractory ovarian cancer using multi-omics analysis in a clinical trial cohort.

bioRxiv · Mar 28, 2024Cancer Biology

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer

I.-M. P. Launonen, E. P. Erkan, I. Niemiec, A. Junquera, M. Hincapie-Otero, D. Afenteva, Z. Liang, M. Salko, A. Szabo, F. Perez-Villatoro, M. M. Falco, Y. Li, G. Micoli, A. Nagaraj, U.-M. Haltia, , A. Farkkila

This study shows chemotherapy causes myeloid-driven spatial T-cell exhaustion in ovarian cancer by altering immune cell states and interactions, suggesting new immunotherapy approaches.

bioRxiv · Mar 19, 2024 · PreprintCancer Biology

Patient-derived functional immuno-oncology platform identifies responders to ATR inhibitor and immunotherapy combinations in ovarian cancer

A. S. Nagaraj, M. Salko, A. Sirsikar, E. P. Erkan, E. A. Pietilä, I. Niemiec, J. Bao, G. Marchi, A. Szabo, K. Nowlan, S. Pikkusaari, A. Kanerva, J. Tapper, R. Koivisto-Korander, L. Kauppi, , A. Färkkilä

bioRxiv · Feb 15, 2024 · PreprintCancer Biology

Evolutionary states and trajectories characterized by distinct pathways stratify ovarian high-grade serous carcinoma patients

A. Lahtinen, K. Lavikka, Y. Li, A. Virtanen, S. Jamalzadeh, K. Huhtinen, O. Carpen, S. Hietanen, A. Häkkinen, J. Hynninen, J. Oikkonen, S. Hautaniemi

This study identifies three evolutionary states of ovarian high-grade serous carcinoma using whole-genome sequencing and links them to distinct therapeutic targets.

bioRxiv · Aug 30, 2022Cancer Biology

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

W. Senkowski, L. Gall-Mas, M. M. Falco, Y. Li, K. Lavikka, M. C. Kriegbaum, J. Oikkonen, D. Bulanova, E. J. Pietras, K. Vossgröne, Y.-J. Chen, E. P. Erkan, M. K. Gronning Hog, I. M. Larsen, T. Lamminen, , K. Wennerberg

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

bioRxiv · Apr 21, 2022Cancer Biology

A three dimensional human immune-tumor cell model reveals the importance of isotypes in antibody-based immunotherapy

S. Lara, J. C. Anania, A. Virtanen, V. Stenhammar, S. Kleinau

The paper evaluates different isotypes of anti-CD20 Rituximab in a 3D tumor model to identify the most effective for tumor cell killing.

bioRxiv · Jul 1, 2020Immunology